Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 6/20 | 0.47 |
| ▸ | PDE2A | O00408 | 4/20 | 0.47 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.47 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.47 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.47 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.47 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | NT5E | P21589 | 7/20 | 0.41 |
| ▸ | CD99 | P14209 | 1/20 | 0.41 |
| ▸ | TMIGD3 | P0DMS9 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL750005 | 1.00 | ADORA3 (0.47) | ADORA3PDE2AADORA2AADORA1ADRA1A | |
| SCHEMBL745409 | 0.85 | ADORA3 (0.64) | ADORA3PDE2AADORA2AADORA1ADRA1A | |
| SCHEMBL745410 | 0.85 | ADORA3 (0.64) | ADORA3PDE2AADORA2AADORA1ADRA1A | |
| SCHEMBL19766042 | 0.84 | HTR2C (0.57) | ADORA3PDE2AADORA2AADORA1ADRA1A | |
| SCHEMBL19766036 | 0.84 | ADORA3 (0.59) | ADORA3ADORA2AADORA1NT5EHTR2C | |
| SCHEMBL14074362 | 0.80 | PDE2A (0.72) | ADORA3PDE2AADORA2AADORA1ADRA1A | |
| SCHEMBL20724578 | 0.80 | ADORA2A (0.45) | ADORA3PDE2AADORA2AADORA1ADRA1A | |
| SCHEMBL10026376 | 0.80 | PDE2A (0.72) | ADORA3PDE2AADORA2AADORA1ADRA1A | |
| SCHEMBL20350734 | 0.80 | PDE2A (0.72) | ADORA3PDE2AADORA2AADORA1ADRA1A | |
| SCHEMBL14086557 | 0.80 | PDE2A (0.72) | ADORA3PDE2AADORA2AADORA1ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149657-A1 | 2'-FLUORO ARABINO NUCLEOSIDES AND USE THEREOF | SOUTHERN RESEARCH INSTITUTE (AL) | 2012-06-14 | — | — | US | disclosed |
| EP-2430034-A1 | 2'-FLUORO ARABINO NUCLEOSIDES AND USE THEREOF | Southern Research Institute (US) | 2012-03-21 | — | — | EP | disclosed |
| WO-2010132513-A1 | 2'-FLUORO ARABINO NUCLEOSIDES AND USE THEREOF | SOUTHERN RESEARCH INSTITUTE (US) | 2010-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149657-A1 | 2'-FLUORO ARABINO NUCLEOSIDES AND USE THEREOF | SLC29A2, DUT, SLC29A1 | ADORA3 203/4885PDE2A 2547/4885ADORA2A 55/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.